Clinical Trials
31 trialsTrial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Canadian Cancer Trials Group
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents
H. Lee Moffitt Cancer Center and Research Institute
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Fox Chase Cancer Center
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Ohio State University Comprehensive Cancer Center
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Texas Southwestern Medical Center
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Washington University School of Medicine
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Columbia University
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
University of California, San Francisco
RID
Yale University
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Depsipeptide to Treat Thyroid and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors
Celgene
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Northwestern University
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
National Cancer Institute (NCI)
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
NYU Langone Health
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma
M.D. Anderson Cancer Center
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Virginia Commonwealth University
A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Depsipeptide in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders
National Cancer Institute (NCI)
FR901228 in Treating Patients With Hematologic Cancer
National Cancer Institute (NCI)
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
National Cancer Institute (NCI)